Smith & Nephew Stock Rating Reaffirmed by AlphaValue (SN)
Smith & Nephew (LON:SN)‘s stock had its “reduce” rating reiterated by stock analysts at AlphaValue in a report issued on Thursday, AnalystRatingsNetwork reports. They currently have a GBX 701 ($11.25) price target on the stock. AlphaValue’s price target suggests a potential downside of 7.21% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Smith & Nephew in a research note to investors on Tuesday. They now have a GBX 740 ($11.87) price target on the stock. Separately, analysts at Credit Suisse reiterated a “neutral” rating on shares of Smith & Nephew in a research note to investors on Wednesday, October 2nd. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of GBX 750.84 ($12.05).
Shares of Smith & Nephew (LON:SN) traded up 0.93% on Thursday, hitting GBX 762.50. The stock had a trading volume of 717,272 shares. Smith & Nephew has a 1-year low of GBX 636.00 and a 1-year high of GBX 805.50. The stock’s 50-day moving average is GBX 778.4 and its 200-day moving average is GBX 761.5. The company’s market cap is £6.901 billion.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.